Plain-English translation of NCT07440147 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a combination of Akkermansia muciniphila (a beneficial gut bacteria) and berberine (a plant-based compound) can help night-shift workers improve their insulin sensitivity and metabolic health. Night-shift work disrupts the body's natural rhythms, leading to problems with how the body handles blood sugar and weight gain. The researchers believe this medication may help restore balance by improving your gut bacteria and metabolism.
Night-shift workers face a higher risk of weight gain, prediabetes, and metabolic problems because their sleep and eating patterns are disrupted by working overnight. This study aims to find out if this medication can help protect shift workers from these health risks by targeting the gut bacteria and the body's internal clock.
You likely qualify if…
You likely don't qualify if…
You will participate for a total of 28 weeks. You'll receive either the medication or a placebo for 12 weeks, then take a 4-week break, then receive the other treatment (or placebo) for another 12 weeks. At four study visits, you'll have your weight, body composition, and blood pressure measured, and you'll provide blood, urine, and stool samples. You'll also complete questionnaires about your diet, sleep, work schedule, and overall health, and keep a food diary for four days before each visit.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
Austria